The identification of tissue transglutaminase as the antigen responsible for endomysial positivity has opened up new horizons for the serological diagnosis of celiac disease. Today the determination of anti-tTG antibodies is the reference test for the diagnosis and follow-up of this disease.

• Eu-tTG IgA New - code 9105, 96 test
  It has been proven that tissue transglutaminase (tTG) is the endomysial autoantigen of coeliac disease.(1)
  Eu-tTG New is the standardised immunological determination of anti-tTG antibodies, recently indicated by the scientific community as the reference test for the diagnosis and follow-up of coeliac disease.
• Eu-tTG IgG New - code 9106, 96 test
  Eu-tTG New can play a fundamental role in both large and specific screening projects, especially for mono-symptomatic or atypical cases where symptoms can be attributed to coeliac disease such as: recurrent abortions, teeth enamel hypoplasia, alopecia, osteoporosis, type I diabetes mellitus, sterility, sideropenic anaemia resistant to iron therapy, epilepsy and others.

Features of the products

• Human recombinant antigen obtained from prokaryotic cells (E.coli)
  to avoid cross-reaction with nuclear eukaryotic antigens
• Calibration curve for a proper patient follow-up
• Ready-to-use reagents
• Unique sample dilution for both IgA and IgG (1:101)
• Total incubation time: 90 minutes at room temperature
• Products manufactured and commercialised by Eurospital, based on the invention of the German scientists Schuppan and Dieterich who provided Eurospital with exclusive world wide licence of use

FDA Clearance

Eu-tTG IgA and IgG, reference kits for the detection of class IgA and IgG antibodies against human tissue transglutaminase, have obtained the FDA 510k clearance on February 7th 2011 (K102964).